TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients
Brief Summary: This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM. Kidney angiomyolipomas are tumors that are made up of blood vessels, muscle and fat. Rapamycin has been approved to treat other diseases, but it is investigational for treating kidney angiomyolipomas.

Investigational means that it is being as a possible treatment for kidney angiomyolipomas but is not currently approved by the U.S. Food and Drug Administration (FDA) for treating this disease.


Options:
A: Arm Label: Everolimus LT target of 3 - 7 ng/mL; Type: EXPERIMENTAL; Interventions: Drug: RAD001, Drug: Antiepileptic drug (1 to 3 only), Drug: open label RAD001 (only used for post-extension phase) | Arm Label: Everolimus HT target of 9 -15 ng/mL; Type: EXPERIMENTAL; Interventions: Drug: RAD001, Drug: Antiepileptic drug (1 to 3 only), Drug: open label RAD001 (only used for post-extension phase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drug (1 to 3 only), Drug: open label RAD001 (only used for post-extension phase) | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): Everolimus HT target of 9 -15 ng/mL, Everolimus LT target of 3 - 7 ng/mL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Antiepileptic drug (1 to 3 only); Assigned to Arm(s): Everolimus HT target of 9 -15 ng/mL, Everolimus LT target of 3 - 7 ng/mL, Placebo | Intervention Type: DRUG; Name: open label RAD001 (only used for post-extension phase); Assigned to Arm(s): Everolimus HT target of 9 -15 ng/mL, Everolimus LT target of 3 - 7 ng/mL, Placebo
B: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
C: Arm Label: Everolimus (RAD001); Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus (RAD001)
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients
Brief Summary: This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM. Kidney angiomyolipomas are tumors that are made up of blood vessels, muscle and fat. Rapamycin has been approved to treat other diseases, but it is investigational for treating kidney angiomyolipomas.

Investigational means that it is being as a possible treatment for kidney angiomyolipomas but is not currently approved by the U.S. Food and Drug Administration (FDA) for treating this disease.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
C: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm
D: Intervention Type: DRUG; Name: Rapamycin, sirolimus; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VISN 23 Lung Disease Self Management/Case Management Program
Brief Summary: The purpose of this study is to determine if a program of self management and case management reduces hospitalizations and urgent care visits for patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program
B: N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Bundle; Type: EXPERIMENTAL; Interventions: Behavioral: Bundle tool | Intervention Type: BEHAVIORAL; Name: Bundle tool; Assigned to Arm(s): Bundle

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VISN 23 Lung Disease Self Management/Case Management Program
Brief Summary: The purpose of this study is to determine if a program of self management and case management reduces hospitalizations and urgent care visits for patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
C: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2
D: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VISN 23 Lung Disease Self Management/Case Management Program
Brief Summary: The purpose of this study is to determine if a program of self management and case management reduces hospitalizations and urgent care visits for patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
B: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VISN 23 Lung Disease Self Management/Case Management Program
Brief Summary: The purpose of this study is to determine if a program of self management and case management reduces hospitalizations and urgent care visits for patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Relaxation Response (instruction, pocket practice card prov), Behavioral: Mindfulness training using model developed from UMass | Intervention Type: BEHAVIORAL; Name: Relaxation Response (instruction, pocket practice card prov); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Mindfulness training using model developed from UMass; Assigned to Arm(s): 2
B: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
C: Arm Label: spirometry, patient activation tool; Type: EXPERIMENTAL; Interventions: Other: provider support tools plus spirometer | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: provider support tools plus spirometer; Assigned to Arm(s): spirometry, patient activation tool
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VISN 23 Lung Disease Self Management/Case Management Program
Brief Summary: The purpose of this study is to determine if a program of self management and case management reduces hospitalizations and urgent care visits for patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: breathing retraining, Other: exercise training | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: exercise training | Intervention Type: OTHER; Name: breathing retraining; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: exercise training; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
C: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)
D: Arm Label: Best available care (BAC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Best available care (BAC) | Arm Label: Telerehabilitation (TH); Type: EXPERIMENTAL; Interventions: Behavioral: Telerehabilitation (TH) | Intervention Type: BEHAVIORAL; Name: Best available care (BAC); Assigned to Arm(s): Best available care (BAC) | Intervention Type: BEHAVIORAL; Name: Telerehabilitation (TH); Assigned to Arm(s): Telerehabilitation (TH)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly - Malawi
Brief Summary: In Malawi, the standard of care to prevent malaria during pregnancy at the time of the study was a two dose sulfadoxine-pyrimethamine intermittent protective treatment (SP IPT) regimen administered in the second and third trimester of pregnancy. In this investigation, this two dose strategy was compared to a monthly SP regimen. The objective for the study was to determine the efficacy of the different regimens for HIV positive and HIV negative women in the prevention of placental malaria.


Options:
A: Intervention Type: DRUG; Name: ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly - Malawi
Brief Summary: In Malawi, the standard of care to prevent malaria during pregnancy at the time of the study was a two dose sulfadoxine-pyrimethamine intermittent protective treatment (SP IPT) regimen administered in the second and third trimester of pregnancy. In this investigation, this two dose strategy was compared to a monthly SP regimen. The objective for the study was to determine the efficacy of the different regimens for HIV positive and HIV negative women in the prevention of placental malaria.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine treatment twice during pregnancy | Arm Label: Monthly SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine at 4-week intervals | Arm Label: AZI-SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine treatment twice during pregnancy; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine at 4-week intervals; Assigned to Arm(s): Monthly SP | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice; Assigned to Arm(s): AZI-SP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life
Brief Summary: This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.


Options:
A: Arm Label: ProQuad®; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): ProQuad®
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3
C: Intervention Type: BIOLOGICAL; Name: Measles, Mumps, Rubella and Chickenpox (live vaccine); Assigned to Arm(s): N/A
D: Arm Label: HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix® | Arm Label: HAV+MMR+V Group; Type: EXPERIMENTAL; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Arm Label: MMR+V→HAV Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix®, Biological: M-M-R®II, Biological: VARIVAX® | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): HAV Group, HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: M-M-R®II; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group | Intervention Type: BIOLOGICAL; Name: VARIVAX®; Assigned to Arm(s): HAV+MMR+V Group, MMR+V→HAV Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Crossover Design Study to Evaluate the Effect of Montelukast Vs. Salmeterol on the Inhibition of Exercise-Induced Bronchoconstriction in Asthmatic Patients Aged 6-14 Years
Brief Summary: The purpose of this study is to determine the effect of four weeks of treatment with two investigational drugs (oral versus inhaled administration) plus an inhaled medication in the treatment of airway constriction brought on by exercise in participants with asthma.


Options:
A: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
D: Arm Label: Montelukast/Salmeterol; Type: EXPERIMENTAL; Interventions: Drug: Montelukast sodium, Drug: Salmeterol xinafoate, Drug: Fluticasone propionate, Drug: Montelukast matching placebo, Drug: Salmeterol matching placebo | Arm Label: Salmeterol/Montelukast; Type: EXPERIMENTAL; Interventions: Drug: Montelukast sodium, Drug: Salmeterol xinafoate, Drug: Fluticasone propionate, Drug: Montelukast matching placebo, Drug: Salmeterol matching placebo | Intervention Type: DRUG; Name: Montelukast sodium; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Montelukast matching placebo; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Salmeterol matching placebo; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder
Brief Summary: This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.


Options:
A: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
B: Arm Label: Group Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Group Behavioral Treatment | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group Behavioral Treatment; Assigned to Arm(s): Group Behavioral Treatment
C: Arm Label: Avatar group; Type: EXPERIMENTAL; Interventions: Other: Avatar group | Arm Label: No Avatar group; Type: ACTIVE_COMPARATOR; Interventions: Other: No Avatar group | Intervention Type: OTHER; Name: Avatar group; Assigned to Arm(s): Avatar group | Intervention Type: OTHER; Name: No Avatar group; Assigned to Arm(s): No Avatar group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2

Answer: D